Upadacitinib 15 mg (Rinvoq) is a medication used for the treatment of various inflammatory conditions, such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), atopic dermatitis (AD), and ulcerative colitis (UC). It is marketed under the brand name Rinvoq and belongs to a class of drugs known as Janus kinase (JAK) inhibitors.

Here’s a detailed description for an e-commerce listing:

Upadacitinib 15 mg (Rinvoq)

Product Overview: Upadacitinib 15 mg (Rinvoq) is a JAK inhibitor used for the treatment of moderate to severe inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, and ulcerative colitis. Rinvoq works by selectively inhibiting Janus kinase (JAK) enzymes, which are involved in the inflammatory process of these diseases, reducing inflammation, pain, and other symptoms.

Key Benefits:

• Effective treatment for rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, and ulcerative colitis.
• Reduces inflammation and improves symptoms, including joint pain, swelling, and skin irritation.
• Convenient oral medication, offering a less invasive alternative to other treatments.

Indications:

• Rheumatoid arthritis (RA): Used in adults for moderate to severe RA who have had an inadequate response or intolerance to methotrexate.
• Psoriatic arthritis (PsA): Indicated for adults with active psoriatic arthritis.
• Atopic dermatitis (AD): Used for the treatment of moderate to severe atopic dermatitis in adults and adolescents.
• Ulcerative colitis (UC): Approved for the treatment of moderate to severe ulcerative colitis in adults.

Dosage:

• 15 mg once daily, taken orally, with or without food.
• Dosage may vary based on the condition being treated. Your healthcare provider will determine the correct dosage and treatment plan.

Precautions:

• Monitor for infections as JAK inhibitors can increase the risk of infections such as tuberculosis.
• Routine screening for infections, liver function, and blood cell counts is important.
• Do not use in combination with other JAK inhibitors or biologics.
• Not recommended for patients with serious liver conditions.

Common Side Effects:

• Upper respiratory tract infections
• Headache
• Nausea
• High blood pressure
• Elevated liver enzymes
• Increased risk of blood clots and other cardiovascular events

Packaging:

• Upadacitinib 15 mg (Rinvoq) tablets are provided in a [insert packaging type] for easy, daily administration.

Important Notes:

• Upadacitinib is intended to be used under the supervision of a healthcare professional.
• Store in a cool, dry place away from direct sunlight.
• Do not take if pregnant, planning to become pregnant, or breastfeeding without consulting your healthcare provider.